Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys -USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S. -Sales of the product for the past 12 months ended March 2024 were $51.8 million

Dr. Reddys

-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.

-Sales of the product for the past 12 months ended March 2024 were $51.8 million Dr. Reddys

-USA Subsidiary, entered a license agreement with Ingenus Pharmaceuticals, LLC for exclusive rights to commercialize Cyclophosphamide Injection RTD in the U.S.

-Sales of the product for the past 12 months ended March 2024 were $51.8 million

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Please follow and like us:
Pin Share

By earn

INTRADAY BUY PIND FOR 2 SEPTEMBER Stocks With Major Volume and News MUTUAL FUND SIP MONEY TRIPPLE IN 10 YEARS FII DATA 18 SEPTEMBER MIDCAP AND SMALL CAP SHARES SELL